HIV and COVID-19: review of clinical course and outcomes
LK Barbera, KF Kamis, SE Rowan… - HIV research & …, 2021 - Taylor & Francis
Background: Understanding the relationship between HIV and SARS-CoV-2 has important
public health implications. Objective: To summarize current research on COVID-19 among …
public health implications. Objective: To summarize current research on COVID-19 among …
Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis
Objectives We aimed to assess the short-term effectiveness of COVID-19 vaccines among
immunocompromised patients to prevent laboratory-confirmed symptomatic COVID-19 …
immunocompromised patients to prevent laboratory-confirmed symptomatic COVID-19 …
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open …
P Bergman, O Blennow, L Hansson, S Mielke… - …, 2021 - thelancet.com
Background Patients with immunocompromised disorders have mainly been excluded from
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in immunocompromised patients–a phase four study comparing …
A Wagner, E Garner-Spitzer, AM Schötta… - Frontiers in …, 2022 - frontiersin.org
Background Individuals with secondary immunodeficiencies belong to the most vulnerable
groups to succumb to COVID-19 and thus are prioritized for SARS-CoV-2 vaccination …
groups to succumb to COVID-19 and thus are prioritized for SARS-CoV-2 vaccination …
COVID-19 convalescent plasma
As the coronavirus disease (COVID-19) pandemic led to a global health crisis, there were
limited treatment options and no prophylactic therapies for those exposed to severe acute …
limited treatment options and no prophylactic therapies for those exposed to severe acute …
Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings
Immunocompromised patients are predisposed to severe COVID-19. Here we compare
homotypic and heterotypic humoral and cellular immune responses to Omicron BA. 1 in …
homotypic and heterotypic humoral and cellular immune responses to Omicron BA. 1 in …
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
L Meyer-Arndt, J Braun, F Fauchere… - Journal of Neurology …, 2022 - jnnp.bmj.com
Background SARS-CoV-2 mRNA vaccination of healthy individuals is highly immunogenic
and protective against severe COVID-19. However, there are limited data on how disease …
and protective against severe COVID-19. However, there are limited data on how disease …
NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins
I Tsukalov, I Sánchez-Cerrillo, O Rajas… - Nature …, 2024 - nature.com
Increased recruitment of transitional and non-classical monocytes in the lung during SARS-
CoV-2 infection is associated with COVID-19 severity. However, whether specific innate …
CoV-2 infection is associated with COVID-19 severity. However, whether specific innate …
Emergence of SARS-CoV-2 spike mutations during prolonged infection in immunocompromised hosts
KKK Ko, H Yingtaweesittikul, TT Tan… - Microbiology …, 2022 - Am Soc Microbiol
Immunocompromised hosts with prolonged severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infections have been implicated in the emergence of highly mutated SARS …
2 (SARS-CoV-2) infections have been implicated in the emergence of highly mutated SARS …
SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 mRNA vaccine
B Clémenceau, T Guillaume, M Coste-Burel, P Peterlin… - Vaccines, 2022 - mdpi.com
Background: At variance to humoral responses, cellular immunity after anti-SARS-CoV-2
vaccines has been poorly explored in recipients of allogeneic hematopoietic stem-cell …
vaccines has been poorly explored in recipients of allogeneic hematopoietic stem-cell …